NON-CLINICAL SAFETY OF PTH-IA, INVERSE AGONIST, TO SUPPORT JANSEN METAPHYSEAL CHONDRODYSPLASIA (JMC) DISEASE.

Iit Research Institute, Chicago IL

Investigators

Abstract

The objective of this study is to determine toxicity and toxicokinetics of PTH-IA after BID daily subcutaneous administration in 7 day old rats for 6 month with a 28 days recovery period.